S
Satoshi Motoya
Researcher at Sapporo Medical University
Publications - 105
Citations - 2819
Satoshi Motoya is an academic researcher from Sapporo Medical University. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 26, co-authored 89 publications receiving 2097 citations.
Papers
More filters
Journal ArticleDOI
Evidence-based clinical practice guidelines for inflammatory bowel disease
Katsuyoshi Matsuoka,Taku Kobayashi,Fumiaki Ueno,Toshiyuki Matsui,Fumihito Hirai,Nagamu Inoue,Jun Kato,Kenji Kobayashi,Kiyonori Kobayashi,Kazutaka Koganei,Reiko Kunisaki,Satoshi Motoya,Masakazu Nagahori,Hiroshi Nakase,Fumio Omata,Masayuki Saruta,Toshiaki Watanabe,Toshiaki Tanaka,Takanori Kanai,Yoshinori Noguchi,Ken Ichi Takahashi,Kenji Watanabe,Toshifumi Hibi,Yasuo Suzuki,Mamoru Watanabe,Kentaro Sugano,Tooru Shimosegawa +26 more
TL;DR: This English version was produced and edited based on the existing updated guidelines for ulcerative colitis and Crohn’s disease in Japanese, developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation system.
Journal ArticleDOI
Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: A prospective, randomized trial
Takayuki Matsumoto,Satoshi Motoya,Kenji Watanabe,Tadakazu Hisamatsu,Hiroshi Nakase,Naoki Yoshimura,Tetsuya Ishida,Shingo Kato,T. Nakagawa,Motohiro Esaki,Masakazu Nagahori,Toshiyuki Matsui,Yuji Naito,Takanori Kanai,Yasuo Suzuki,Masanori Nojima,Mamoru Watanabe,Toshifumi Hibi +17 more
TL;DR: The clinical efficacy of a combination of adalimumab and azathioprine at WWeek 26 did not differ from that of ad alimumab monotherapy in patients with active Crohn's disease naïve to both medications.
Journal ArticleDOI
A Genome-Wide Association Study Identifies 2 Susceptibility Loci for Crohn's Disease in a Japanese Population
Keiko Yamazaki,Junji Umeno,Atsushi Takahashi,Atsushi Hirano,Todd A. Johnson,Natsuhiko Kumasaka,Takashi Morizono,Naoya Hosono,Takaaki Kawaguchi,Masakazu Takazoe,Tetsuhiro Yamada,Yasuo Suzuki,Hiroki Tanaka,Satoshi Motoya,Masayo Hosokawa,Yoshiaki Arimura,Yasuhisa Shinomura,Toshiyuki Matsui,Takayuki Matsumoto,Mitsuo Iida,Tatsuhiko Tsunoda,Yusuke Nakamura,Naoyuki Kamatani,Michiaki Kubo +23 more
TL;DR: In a genome-wide association study, 2 new susceptibility loci for Crohn's disease in the Japanese population are identified and could increase the understanding of the pathogenesis of Crohn’s disease.
Journal ArticleDOI
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki,Satoshi Motoya,Hiroyuki Hanai,Takayuki Matsumoto,Toshifumi Hibi,Anne M. Robinson,Nael M. Mostafa,Jingdong Chao,Vipin Arora,Anne Camez,Roopal Thakkar,Mamoru Watanabe +11 more
TL;DR: Investigation of adalimumab for induction and maintenance treatment in 273 anti-TNF–naive Japanese patients with UC found it led to early response and mucosal healing, and maintenance ad alimumab had greater rates of long-term response, remission, and mucosa healing compared with placebo.
Journal ArticleDOI
An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment
Atsushi Sakuraba,Satoshi Motoya,Kenji Watanabe,Masakazu Nishishita,Kazunari Kanke,Toshiyuki Matsui,Yasuo Suzuki,Tadayuki Oshima,Reiko Kunisaki,Takayuki Matsumoto,Hiroyuki Hanai,Ken Fukunaga,Naoki Yoshimura,Toshimi Chiba,Shinsuke Funakoshi,Nobuo Aoyama,Akira Andoh,Hiroshi Nakase,Yohei Mizuta,Ryoichi Suzuki,Taiji Akamatsu,Masahiro Iizuka,Toshifumi Ashida,Toshifumi Hibi +23 more
TL;DR: Intensive GMA in patients with active UC seems to be more efficacious than weekly treatment, and significantly reduced the patients' morbidity time without increasing the incidence of side effects.